Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
2006-001007-11Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jul 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan, oxaliplatin, fluorouracil and levoleucovorin in metastatic colon cancer (mCRC) and colon cancer, sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoints: Progression-free survival and Response rate. Started Jul 2007; status: active.
02
Drugs
bevacizumabirinotecanoxaliplatinfluorouracillevoleucovorin
03
Conditions
metastatic colon cancer (mCRC)colon cancer
Beyond the preview
Go deeper on 2006-001007-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001007-11.